摘要
目的:急性缺血性脑卒中(acute ischemic stroke,AIS)是我国常见且致残率、死亡率较高的脑血管疾病,药物治疗在改善预后中具有重要作用。丁苯酞、依达拉奉、尤瑞克林及依达拉奉右莰醇为临床常用药物,本文旨在通过临床综合评价明确其临床应用价值。方法:从有效性、安全性、经济性、可及性和适宜性5个维度,基于文献和公开数据对上述药物进行评价。结果:评价药品之间的有效性和安全性差异不显著,但丁苯酞在累积排序曲线下面积(surface under the cumulative ranking curve,SUCRA)排序中优效性概率相对更高,在使用便利性、医保覆盖和患者负担等方面表现更优,综合适宜性较好,临床上可结合患者需求进行选择。结论:丁苯酞在AIS的治疗中具有较好的综合临床价值,尤其在经济性和适宜性方面表现优越,本研究可为相关药物政策制定和临床用药决策提供参考依据。
Objective:To conduct a comprehensive clinical evaluation of drugs for acute ischemic stroke(AIS)such as butylphthalide,edaravone,uricilin,and edaravone borneol to clarify their clinical application values.Methods:This study evaluated the aforementioned drugs from five dimensions:efficacy,safety,cost-effectiveness,accessibility,and appropriateness,based on literature and publicly available data.Results:There were no significant differences in efficacy and safety among the evaluated drugs.However,butylphthalide showed a relatively higher probability of superiority in the surface under the cumulative ranking curve(SUCRA)ranking.Additionally,it performed better in terms of use convenience,medical insurance coverage,and patient cost burden,resulting in good comprehensive suitability.Clinicians can make selections based on patients' specific needs.Conclusion:Butylphthalide has better comprehensive clinical value in the treatment of acute ischemic stroke,especially in terms of cost-effectiveness and appropriateness.This study can provide a reference for the formulation of relevant drug policies and clinical medication decisions.
作者
王雨菲
嵇欣悦
田磊
WANG Yu-fei;JI Xin-yue;TIAN Lei(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China;Center of Pharmacoeconomic Evaluation,China Pharmaceutical University,Nanjing 211198,China)
出处
《中国新药杂志》
北大核心
2026年第2期213-219,共7页
Chinese Journal of New Drugs
